Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial - Concepedia

Concepedia

Publication | Open Access

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

DOI Full Paper Access

272

Citations

12

References

2023

Year

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, Jung‐Yun Lee, Jessica Thomes Pepin, Michael J. Sundborg, Ayelet Shai, Joseph de la Garza, Shin Nishio, Michael A. Gold,

Journal of Clinical Oncology

Abstract

Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer.

References

	Year	Citations

Page 1